Citigroup upgraded Core Labs from Sell to Neutral and set a new price target of $16.00 from $15.00 previously
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/12/2025 | $15.00 → $16.00 | Sell → Neutral | Citigroup |
| 6/30/2023 | $22.00 → $21.00 | Neutral → Sell | Citigroup |
| 4/18/2023 | $21.50 | Neutral → Underperform | BofA Securities |
| 1/9/2023 | Underperform → Neutral | BofA Securities | |
| 10/7/2022 | $24.00 → $17.00 | Sell → Neutral | Citigroup |
| 9/26/2022 | $20.00 | Equal-Weight → Underweight | Morgan Stanley |
| 4/18/2022 | $19.50 → $21.30 | Neutral → Underweight | Piper Sandler |
| 1/18/2022 | $32.00 → $30.00 | Equal-Weight | Morgan Stanley |
SCHEDULE 13G/A - Core Laboratories Inc. /DE/ (0001958086) (Subject)
SCHEDULE 13G/A - Core Laboratories Inc. /DE/ (0001958086) (Subject)
10-Q - Core Laboratories Inc. /DE/ (0001958086) (Filer)
REVENUE OF $130.2 MILLION, UP 5% SEQUENTIALLY AND FLAT YEAR-OVER-YEAROPERATING INCOME OF $15.3 MILLION; EX-ITEMS, $14.5 MILLION, UP OVER 23% SEQUENTIALLY AND DOWN 11% YEAR-OVER-YEAROPERATING MARGINS, EX-ITEMS, OF 11%, EXPANDED 160 BASIS POINTS SEQUENTIALLY, WITH INCREMENTAL MARGINS, EX-ITEMS, OF 41%GAAP EPS OF $0.22; EX-ITEMS, $0.19, UP 33% SEQUENTIALLY, AND DOWN 14% YEAR-OVER-YEARCOMPANY REPURCHASED 237,632 SHARES OF COMMON STOCK, A VALUE OF $2.7 MILLION FREE CASH FLOW OF $10.4 MILLION, UP OVER 160% SEQUENTIALLYNET DEBT REDUCED BY $9.1 MILLION; DEBT LEVERAGE RATIO IMPROVED TO 1.27 COMPANY ANNOUNCES Q2 2025 QUARTERLY DIVIDEND HOUSTON, July 23, 2025 /PRNewswire/ -- Core Laboratories Inc. (NYS
HOUSTON, June 24, 2025 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will host its second quarter 2025 conference call for investors and analysts at 7:30 a.m. CDT / 8:30 a.m. EST on July 24, 2025. Larry Bruno, Chairman and CEO, Chris Hill, CFO, and Gwen Gresham, SVP Corporate Development and Investor Relations, will discuss financial and operational results. An earnings press release will be issued after market close on July 23, 2025, and may be accessed through the Company's website at www.corelab.com. To register for the listen-only webcast, log on to www.corelab.com at least fifteen minutes prior to the start of the call. For those not available to listen to the live webcast, a replay a
HOUSTON, May 7, 2025 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core Lab", or the "Company") is pleased to announce the opening of its new Unconventional Core Analysis Laboratory in Dammam, Kingdom of Saudi Arabia. This state-of-the-art facility, developed in collaboration with Core's long-time partner, Abdulla Fouad Group, underscores the Company's commitment to advancing reservoir evaluation technologies in the Middle East. The Company's new analytical laboratory is equipped with advanced proprietary instrumentation designed to provide comprehensive core and fluid analysis services tailored to unconventional reservoirs. By bringing Core Lab's cutting-edge technologies t
Citigroup upgraded Core Labs from Sell to Neutral and set a new price target of $16.00 from $15.00 previously
Citigroup downgraded Core Labs from Neutral to Sell and set a new price target of $21.00 from $22.00 previously
BofA Securities downgraded Core Labs from Neutral to Underperform and set a new price target of $21.50
4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
3 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
SC 13G/A - CORE LABORATORIES N V (0001000229) (Subject)
SC 13G/A - CORE LABORATORIES N V (0001000229) (Subject)
SC 13G/A - CORE LABORATORIES N V (0001000229) (Subject)
REVENUE OF $130.2 MILLION, UP 5% SEQUENTIALLY AND FLAT YEAR-OVER-YEAROPERATING INCOME OF $15.3 MILLION; EX-ITEMS, $14.5 MILLION, UP OVER 23% SEQUENTIALLY AND DOWN 11% YEAR-OVER-YEAROPERATING MARGINS, EX-ITEMS, OF 11%, EXPANDED 160 BASIS POINTS SEQUENTIALLY, WITH INCREMENTAL MARGINS, EX-ITEMS, OF 41%GAAP EPS OF $0.22; EX-ITEMS, $0.19, UP 33% SEQUENTIALLY, AND DOWN 14% YEAR-OVER-YEARCOMPANY REPURCHASED 237,632 SHARES OF COMMON STOCK, A VALUE OF $2.7 MILLION FREE CASH FLOW OF $10.4 MILLION, UP OVER 160% SEQUENTIALLYNET DEBT REDUCED BY $9.1 MILLION; DEBT LEVERAGE RATIO IMPROVED TO 1.27 COMPANY ANNOUNCES Q2 2025 QUARTERLY DIVIDEND HOUSTON, July 23, 2025 /PRNewswire/ -- Core Laboratories Inc. (NYS
HOUSTON, June 24, 2025 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will host its second quarter 2025 conference call for investors and analysts at 7:30 a.m. CDT / 8:30 a.m. EST on July 24, 2025. Larry Bruno, Chairman and CEO, Chris Hill, CFO, and Gwen Gresham, SVP Corporate Development and Investor Relations, will discuss financial and operational results. An earnings press release will be issued after market close on July 23, 2025, and may be accessed through the Company's website at www.corelab.com. To register for the listen-only webcast, log on to www.corelab.com at least fifteen minutes prior to the start of the call. For those not available to listen to the live webcast, a replay a
REVENUE OF $123.6 MILLION, DOWN 4% SEQUENTIALLY AND 5% YEAR-OVER-YEAROPERATING INCOME OF $4.4 MILLION; EX-ITEMS, $11.8 MILLION, DOWN 25% SEQUENTIALLY AND 21% YEAR-OVER-YEAROPERATING MARGINS, EX-ITEMS, OF 10% GAAP EPS OF $0.00; EX-ITEMS, $0.14, DOWN 35% SEQUENTIALLY, AND 25% YEAR-OVER-YEARFREE CASH FLOW OF $3.9 MILLION, UP OVER 50% YEAR-OVER-YEAR NET DEBT REDUCED BY $4.9 MILLION; DEBT LEVERAGE RATIO REMAINS AT 1.31 COMPANY REPURCHASED 131,598 SHARES OF COMMON STOCK, A VALUE OF $2.0 MILLION COMPANY ANNOUNCES Q1 2025 QUARTERLY DIVIDEND HOUSTON, April 23, 2025 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core Lab", or the "Company") reported first quarter 2025 revenue of $123,6